In order to explore whether HRRmut is also associated with the benefit of anti-PD-1/L1 therapy, we performed data analysis on the Samstein2018 cohort with 130 advanced melanoma patients who received anti-PD-1/L1 therapy, of which 35 patients (26.9%) harbored HRRmut. Here, PDCD1 is linked to melanoma.